Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women.
This nanomedicine based drug delivery approach, provides selective delivery of targeted chemotherapy agents, minimising side effects and developing pharmacokinetic properties, thus improving quality of life for patients. The nanomedicine has a special water-soluble bio-compatible macromolecular carrier that contains a covalent bond with the active drug agent, thus preventing the problem of burst , providing a better side-effect profile .
This technology is targeted for breast cancer treatment: special polymeric carrier and linker, transporting the medicine directly to the tumour. The system can deliver higher amounts and multiple drugs per dose minimising side effects and increasing efficacy, benefiting patients.
Common polymeric carriers in the market can only accommodate maximum two molecules of cargo, whereas this system can carry multiple attachments with a degree of freedom on polymer length.
Statistics display a projection of the top 10 therapeutic areas globally and projected CAGR (fee-based) from 2015 to 2020. During this time, breast cancer is expected to have a compound annual growth rate of 13 per cent.
Indicated in a report by Statista, there will be 6 breast cancer treatment drugs in the top 20 revenue-generating cancer drugs in 2020, and their revenue share out of these top 20 cancer drugs is projected to be USD20 billion.
In 2014, out of the top 10 cancer medicines, there are 2 breast cancer treatment drugs that have generated a revenue of USD8.4 billion.